• 1.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

  • 2.

    de Boer IA, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98:S1−S115. doi: 10.1016/j.kint.2020.06.019

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

  • 4.

    Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:14131424. doi: 10.1056/NEJMoa2022190

  • 5.

    Haller H, et al. Finerenone: A new mineralocorticoidreceptor antagonist without hyperkalemia: An opportunity in patients with CKD? Curr Hypertens Rep 2016; 18:41. doi: 10.1007/s11906-016-0649-2

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:22192229. doi: 10.1056/NEJMoa2025845

    • Crossref
    • Search Google Scholar
    • Export Citation

Diabetic (and Non-Diabetic) Kidney Disease Enters a New Era

  • 1 Susan Murray, MB, BAO, MRCPI, is a nephrology fellow at Duke University, Durham, NC. Matthew A. Sparks, MD, is Assistant Professor of Medicine; Associate Program Director of Nephrology Fellowship; and Director of Medical Student Research, Department of Medicine, Duke University, and Staff Physician, Durham VA Health Care System, Durham, NC.
Restricted access
Save